MANUFACTURING SERVICES AGREEMENT FOR PATISIRAN (ALN-TTR02)Manufacturing Services Agreement • May 4th, 2018 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS MANUFACTURING SERVICES AGREEMENT is made as of March 28, 2018 (the “Effective Date”) by and between ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation with an office at 300 Third Street, Cambridge, MA 02142 (together with its Affiliates, collectively, “Alnylam”) and Agilent Technologies, Inc., a Delaware corporation with an office at 5555 Airport Blvd, Suite 100, Boulder, CO 80301 (“Manufacturer”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 4th, 2018 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”), is entered into as of January 6, 2018 (the “Execution Date”), is entered into by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Alnylam”), and Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (“Genzyme”). Except where otherwise specifically provided herein, the rights and obligations set forth herein shall only become binding upon the Effective Date (which, when used in this Agreement, has the meaning provided in Amendment No. 2 (as defined herein)).
AMENDMENT No. 2 TO THE COLLABORATION AGREEMENTThe Collaboration Agreement • May 4th, 2018 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 2 TO THE COLLABORATION AGREEMENT (this “Collaboration Amendment” or this “Agreement”), entered into as of January 6, 2018 (the “Execution Date”), is entered into by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Alnylam”) and Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (“Genzyme”).
ALN-AT3 Global License TermsGlobal License Terms • May 4th, 2018 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
THESE ALN-AT3 GLOBAL LICENSE TERMS (this “Agreement”) are entered into as of January 6, 2018 (the “Execution Date”), by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Alnylam”), and Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (“Genzyme”). Except where otherwise specifically provided herein, the rights and obligations set forth herein shall only become binding upon the Effective Date (which, when used in this Agreement, has the meaning provided in Amendment No. 2 (as defined herein)).
